Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Metagenomi, Inc. (MGX)

Core Viewpoint - The article discusses a class action lawsuit against Metagenomi, Inc. following its IPO, highlighting the deadline for investors to file a lead plaintiff motion and the alleged misleading statements made by the company regarding its collaboration with Moderna [1][4]. Group 1: Company Overview - Metagenomi, Inc. conducted its IPO on February 13, 2024, selling approximately 6.25 million shares at $15 per share [3]. - Following the announcement of the termination of its collaboration with Moderna on May 1, 2024, Metagenomi's stock price dropped by $0.87, or 12.4%, closing at $6.17 per share on May 2, 2024 [3]. Group 2: Legal Proceedings - A class action lawsuit has been filed on behalf of investors who purchased Metagenomi securities during the IPO, with a deadline of November 25, 2024, to file a lead plaintiff motion [1][6]. - The complaint alleges that the defendants made materially false and misleading statements and failed to disclose adverse facts about the company's business and prospects, particularly regarding the collaboration with Moderna [4].